Sharpe Brain Cancer Research Awards

Our sponsors, donors, and walk attendees were essential in helping us raise funds in our inaugural 5K Run/Walk, on behalf of the 2017 beneficiary, the National Brain Tumor Society. Your participation and contributions helped to support efforts to battle the affliction from which more than 700,000 people in America suffer.

Without the generous contributions of our supporters, we wouldn’t have been able to make the walk such an outstanding success

To continue to support brain cancer research in 2018, we have invited these same 10  institutions to submit their best ideas to cure brain cancer. (1st place will receive $100,000, 2nd place will receive $50,000 and 3rd place will receive $25,000.)

We are optimistic that this initiative will produce significant advances based on the brain cancer research that we’re funding. These projects include:

1) Developing effective therapeutics of targeted- and Immuno-therapy GBM,” PI: Jean Zhao, PhD, Co-PI: Patrick Wen, MD, Dana-Farber Cancer Institute

2) Pritumumab Immunotherapy for Glioblastoma, PI: Santosh Kesari, MD, PhD, John Wayne Cancer Institute

3) Targeting the glioma immune environment by creating tertiary lymphoid organs, Co-PIs: Susan Chang, MD and Hideho Okada, MD, PhD, University of California, San Francisco

4) Identifying and targeting metabolic co-dependency pathways in GBM: an unbiased systematic approach, PI: Paul Mischel, Ludwig Institute for Cancer Research

5) Elucidating the dynamics of immune-reactive signatures in glioblastoma, PI: Timothy Cloughesy, MD, Co-PI: David Nathanson, PhD, University of California, Los Angeles

6) In-situ mapping of GBM tumor microenvironment, PI: Ingo Mellinghoff, MD, Co-PI: Travis Hollmann, MD, PhD, Memorial Sloan Kettering Cancer Center

7) Combining PVSRIPO Immunotherapy with Chemotherapy for the Treatment of Recurrent GBM,PI: Matthias Gromeier, MD, Co-PI: Annick Desjardins, MD, Duke University

8) Immunotherapy for Brain Tumors Through APOBEC3B-induced Neo-epitope Generation in Combination with Immune Checkpoint Blockade, PI: Richard Vile, PhD, Co-PI: Brian Patrick ’Neill, MD, Mayo Clinic

9) PDL1 expression and regulation in glioblastoma stem cells, PI: Veerakumar Balasubramaniyan, Co-PI: John de Groot, MD, University of Texas MD Anderson Cancer Center

10) Targeting IL-6 to strengthen immunotherapy for GBM,PI: Yi Fan, MD PhD, Co-PI: Steven Brem, MD, University of Pennsylvania